Navigation Links
Reata's Synthetic Triterpenoids Profiled in Nature Reviews Cancer

that RTA 402 has potent single-agent anti-cancer activity in patients with several different types of tumors, is exceptionally well tolerated with only mild, transient side effects, inhibits the activity of NF-kB and STAT3 (the drug's targets) in human tumors, and is able to suppress levels of tumor promoting cytokines and growth factors (for example, TNF and VEGF) at very low doses. Reata is also advancing a second Synthetic Triterpenoid capable of crossing the blood-brain barrier for neurological indications including multiple sclerosis, Alzheimer's disease, and Parkinson's disease. This agent is in advanced preclinical development.

In the "Nature Reviews Cancer" article, the researchers provide a comprehensive overview of the discovery and activity of these agents. The authors note that Reata's Synthetic Triterpenoids have profound effects on inflammation and the redox state of cells and tissues, as well as being potent anti-proliferative and pro-apoptotic agents. Because of their unique pharmacology, these agents are being studied at leading research institutions and are the subject of more than 50 publications in peer reviewed journals. The article summarizes the current state of this literature. Some highlights of this comprehensive body of research reviewed in the article include the following:

-- How the drugs were optimized to inhibit the de novo synthesis of iNOS and COX2 in normal mouse macrophages. iNOS and COX2 have essential roles in the initiation of inflammation.

-- An explanation of the drugs' molecular targets and mechanism of action. The synthetic triterpenoids are potent inhibitors of transcription factors such as NF-kB and the STATs that are normally activated by reactive oxygen and nitrogen species. Inhibition is achieved by activation of the antioxidant transcription factor Nrf2, which activates the phase 2 genes and reduces cellular levels of reactive oxygen and nitrogen species. In addition, the triterpenoids directly re
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Positive Statistical Analysis from Synthetic Bloods Oxycyte Traumatic Brain Injury Trial Indicates Achievement of Primary Endpoint
2. Mode of Action of EpiCept-Licensed Cancer Compound Profiled at AACR
3. Targeting Specific Mutations Reveals Promising New Approach to Treating Genetic Disorders; Preclinical Data Published in Nature
4. MedImmune Publishes New Data in Nature Immunology Demonstrating The Role HMGB1 May Play in Systemic Autoimmune Diseases
5. Critical Therapeutics Announces the Publication of New Preclincial HMGB1 Data in Nature Immunology
6. Aeolus Pharmaceuticals AEOL 10150 Highlighted in Nature Genetics Publication
7. Neuroblastoma Expert Reviews Progress and Challenges in Fighting Difficult Pediatric Cancer
8. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
9. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
10. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
11. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Reata Synthetic Triterpenoids Profiled Nature Reviews Cancer
(Date:8/3/2015)... Pa. , Aug. 3, 2015 VWR ... laboratory products, services and solutions, announces the redesign of its ... customers. When visiting the new site, guests ... with bold colors and vivid images.  Each country site now ... an A to Z product menu; and , the ...
(Date:8/3/2015)... SPRINGS, Florida , August 3, 2015 /PRNewswire/ ... HOLD -- FN Media Group LLC, PIV757417 The ... Focus on Developing Orphan Drug Products & Treatments ... now OFF HOLD. Distribution time: 3 Aug 2015 ... agreements between biotech companies, military surgical research and ...
(Date:8/3/2015)... 2015  Charleston Laboratories, Inc., an emerging specialty ... development program with a Phase 1 study on ... CL-H1T contains fast-dissolving promethazine and sumatriptan.  This novel ... for migraine headache pain and migraine-induced nausea and ... migraine headaches also suffer from nausea and vomiting," ...
Breaking Medicine Technology:VWR's New Website Redesign Provides Improved Functionality for Customers 2/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 2/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 3/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 4/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 5/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 6Charleston Laboratories, Inc. Initiates Patient Enrollment in a Phase 1 Study of Charleston's Second Product, CL-H1T 2
... , AUSTIN, Texas, Dec. 9 Ascension ... recent hiring of two veteran executives, L. Robert Johnston, Jr. ... Vice President of Marketing. "These individuals bring a wealth of ... future growth of Ascension," said Guy Mayer, CEO. "As members ...
... Dec. 9 BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX ) ... to the Company,s Board of Directors. Dr. Sanders brings ... physician and professor of medicine. , "We are ... said Zola P. Horovitz, Ph.D., Chairman of the Board of ...
Cached Medicine Technology:Ascension Orthopedics Hires Key Senior Executives 2BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 2BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 3BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 4
(Date:8/3/2015)... ... ... an opinion piece published July 28 by the Washington Post, the conventional wisdom ... may not be accurate. While this system may work for some people, the author notes ... both on the individual and at what point that person is in their weight loss ...
(Date:8/3/2015)... ... August 03, 2015 , ... BESLER Consulting today ... B2B Awards. , The MarketingProfs Bright Bulb B2B Awards celebrate the best marketing, ... for the launch of their Readmissions Analytics product was selected as one of ...
(Date:8/3/2015)... ... August 03, 2015 , ... A ... while an overwhelming number of Hispanics believe people can positively affect their diabetes, ... of participants queried said making diet changes was important. Far fewer participants mentioned ...
(Date:8/3/2015)... ... August 03, 2015 , ... Social impact ... AUGUST 3, 2015 – Since winning a South by Southwest® (SXSW®) Interactive Innovation ... an organization whose mission is to develop technology for the sake of humanity ...
(Date:8/3/2015)... ... August 03, 2015 , ... AxoGen, Inc. (NASDAQ: AXGN), a leader ... present at the Wedbush Healthcare Conference on Wednesday, August 12, 2015 at 9:45am (ET) ... archived replay of the Company’s presentation may be accessed via the investor relations section ...
Breaking Medicine News(10 mins):Health News:Article Dispelling Weight Loss Myth Correctly Emphasizes the Complicated and Difficult Nature of Weight Loss, Says Dr. Michael Feiz 2Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 2Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 3Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 4Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 2Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 3Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 4Health News:AxoGen, Inc. to Present at the Wedbush Healthcare Conference 2
... Pediatric rankings include top 30 hospitals in six specialty fields ... ... 30 U.S.News & World Report, one of the,nation,s leading sources of ... Children,s Hospitals,published online at http://www.usnews.com/pediatrics and in the magazine,s,June 9 ...
... Company to evaluate appeal options, TORONTO, May ... PMD; Amex: PME) today announced it has been ... it will not continue to,support PreMD,s plan for ... it intends to delist the Company,s common stock ...
... cancer were more likely than whites to die in ... among blacks for life-extending treatment even in the face ... by researchers at Dana-Farber Cancer Institute in Boston. ,The ... meeting of the American Society of Clinical Oncology in ...
... finds , , FRIDAY, May 30 (HealthDay News) -- Cirque ... to those of elite athletes in competitive sports, say ... 2006. , Injuries of the knee and ankle were ... all injuries to the upper extremities. Most injuries (45 ...
... GLENWOOD, Ill., May 30 Landauer, Inc. (NYSE:,LDR) announced ... cash dividend of $0.50 per share for the third ... July 3, 2008, to shareholders of record,on June 13, ... provider of analytical services to determine,occupational and environmental radiation ...
... One of the Easiest Paths to Fitness, INDIANAPOLIS, May ... fitness method, think again: taking a stroll is,an easy way ... according to three researchers who presented findings today at the,55th ... A study of 14 morbidly obese patients was designed to ...
Cached Medicine News:Health News:U.S.News & World Report Debuts First Specialty Rankings of America's Best Children's Hospitals 2Health News:U.S.News & World Report Debuts First Specialty Rankings of America's Best Children's Hospitals 3Health News:Delisting Notification Received from the American Stock Exchange 2Health News:Black patients with terminal cancer more likely to choose aggressive care at end of life 2Health News:Injury Patterns Similar for 'Circus' Artists, Elite Athletes 2Health News:Brisk Walking Lowers Blood Pressure, Increases Fitness in Obese 2
Bechert-McPherson tying forceps, angled, 10 mm tying platforms....
Shepard tying forceps, round curved platform 8 mm, 8.5 cm....
Girard curved tying forceps made of titanium has curved shafts with 8 mm tying platforms, width of shafts 0,25 mm, TCI platforms, round handle, diam. 6 mm, overall length 99 mm....
Girard straight tying forceps made of titanium has straight shafts with 6 mm tying platforms, width of shafts 0,25 mm, TCI platforms, round handle, diam. 6 mm, overall length 105 mm....
Medicine Products: